Search

Your search keyword '"Humphries, Matthew"' showing total 180 results
Start Over Author "Humphries, Matthew" Publication Year Range Last 10 years
180 results on '"Humphries, Matthew"'

1. Activation of a cGAS-STING-mediated immune response predicts response to neoadjuvant chemotherapy in early breast cancer

Author

Parkes, Eileen E., Savage, Kienan I., Lioe, Tong, Boyd, Clinton, Halliday, Sophia, Walker, Steven M., Lowry, Keith, Knight, Laura, Buckley, Niamh E., Grogan, Andrena, Logan, Gemma E., Clayton, Alison, Hurwitz, Jane, Kirk, Stephen J., Xu, Jiamei, Sidi, Fatima Abdullahi, Humphries, Matthew P., Bingham, Victoria, James, Jaqueline A., James, Colin R., Paul Harkin, D., Kennedy, Richard D., and McIntosh, Stuart A.

Published
2022
Full Text
View/download PDF

2. Male Breast Cancer

Author

Speirs, Valerie, Humphries, Matthew P., Shaaban, Abeer M., van Krieken, J. H. J. M., Series Editor, Sapino, Anna, editor, and Kulka, Janina, editor

Published
2020
Full Text
View/download PDF

4. Topographic analysis of pancreatic cancer by TMA and digital spatial profiling reveals biological complexity with potential therapeutic implications.

Author

Bingham, Victoria, Harewood, Louise, McQuaid, Stephen, Craig, Stephanie G., Revolta, Julia F., Kim, Chang S., Srivastava, Shambhavi, Quezada-Marín, Javier, Humphries, Matthew P., and Salto-Tellez, Manuel

Subjects
NUCLEOTIDE sequencing, PANCREATIC cancer, GENE expression, PANCREATIC duct, TUMOR markers, INTROGRESSION (Genetics)
Abstract

Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal human malignancies. Tissue microarrays (TMA) are an established method of high throughput biomarker interrogation in tissues but may not capture histological features of cancer with potential biological relevance. Topographic TMAs (T-TMAs) representing pathophysiological hallmarks of cancer were constructed from representative, retrospective PDAC diagnostic material, including 72 individual core tissue samples. The T-TMA was interrogated with tissue hybridization-based experiments to confirm the accuracy of the topographic sampling, expression of pro-tumourigenic and immune mediators of cancer, totalling more than 750 individual biomarker analyses. A custom designed Next Generation Sequencing (NGS) panel and a spatial distribution-specific transcriptomic evaluation were also employed. The morphological choice of the pathophysiological hallmarks of cancer was confirmed by protein-specific expression. Quantitative analysis identified topography-specific patterns of expression in the IDO/TGF-β axis; with a heterogeneous relationship of inflammation and desmoplasia across hallmark areas and a general but variable protein and gene expression of c-MET. NGS results highlighted underlying genetic heterogeneity within samples, which may have a confounding influence on the expression of a particular biomarker. T-TMAs, integrated with quantitative biomarker digital scoring, are useful tools to identify hallmark specific expression of biomarkers in pancreatic cancer. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

7. Whole-genome sequencing uncovers the genomic determinants of therapeutic resistance to immune checkpoint blockade

Author

Litchfield, Kevin, primary, Simpson, Benjamin, additional, Cha, Hongui, additional, Castro, Andrea, additional, Bentham, Robert, additional, Ryan, Lucy, additional, Dietzen, Michelle, additional, Thol, Kerstin, additional, Kinnersley, Ben, additional, Martin, Alice, additional, Chubb, Daniel, additional, Cornish, Alex, additional, Coulton, Alex, additional, Thakkar, Krupa, additional, Bailey, Chris, additional, Jennings, Charlotte, additional, Kaye, Danny, additional, Bansal, Daljeet, additional, Humphries, Matthew, additional, Wright, Alexander, additional, Colquhoun, Catherine, additional, Stankeviciute, Gaby, additional, Helliwell, Jacob, additional, Arumugam, Prabhu, additional, Treanor, Darren, additional, McGranahan, Nicholas, additional, Larkin, James, additional, Turajlic, Samra, additional, Swanton, Charles, additional, Greenig, Juliane, additional, Hiley, Crispin, additional, and Consortium, GEL Genomics England Research, additional

Published
2023
Full Text
View/download PDF

8. Immune status is prognostic for poor survival in colorectal cancer patients and is associated with tumour hypoxia

Author

Craig, Stephanie G., Humphries, Matthew P., Alderdice, Matthew, Bingham, Victoria, Richman, Susan D., Loughrey, Maurice B., Coleman, Helen G., Viratham-Pulsawatdi, Amelie, McCombe, Kris, Murray, Graeme I., Blake, Andrew, Domingo, Enric, Robineau, James, Brown, Louise, Fisher, David, Seymour, Matthew T., Quirke, Phil, Bankhead, Peter, McQuaid, Stephen, Lawler, Mark, McArt, Darragh G., Maughan, Tim S., James, Jacqueline A., and Salto-Tellez, Manuel

Published
2020
Full Text
View/download PDF

12. Data from Metastasis and Immune Evasion from Extracellular cGAMP Hydrolysis

Author

Li, Jun, primary, Duran, Mercedes A., primary, Dhanota, Ninjit, primary, Chatila, Walid K., primary, Bettigole, Sarah E., primary, Kwon, John, primary, Sriram, Roshan K., primary, Humphries, Matthew P., primary, Salto-Tellez, Manuel, primary, James, Jacqueline A., primary, Hanna, Matthew G., primary, Melms, Johannes C., primary, Vallabhaneni, Sreeram, primary, Litchfield, Kevin, primary, Usaite, Ieva, primary, Biswas, Dhruva, primary, Bareja, Rohan, primary, Li, Hao Wei, primary, Martin, Maria Laura, primary, Dorsaint, Princesca, primary, Cavallo, Julie-Ann, primary, Li, Peng, primary, Pauli, Chantal, primary, Gottesdiener, Lee, primary, DiPardo, Benjamin J., primary, Hollmann, Travis J., primary, Merghoub, Taha, primary, Wen, Hannah Y., primary, Reis-Filho, Jorge S., primary, Riaz, Nadeem, primary, Su, Shin-San Michael, primary, Kalbasi, Anusha, primary, Vasan, Neil, primary, Powell, Simon N., primary, Wolchok, Jedd D., primary, Elemento, Olivier, primary, Swanton, Charles, primary, Shoushtari, Alexander N., primary, Parkes, Eileen E., primary, Izar, Benjamin, primary, and Bakhoum, Samuel F., primary

Published
2023
Full Text
View/download PDF

13. Supplementary Data PDF from Metastasis and Immune Evasion from Extracellular cGAMP Hydrolysis

Author

Li, Jun, primary, Duran, Mercedes A., primary, Dhanota, Ninjit, primary, Chatila, Walid K., primary, Bettigole, Sarah E., primary, Kwon, John, primary, Sriram, Roshan K., primary, Humphries, Matthew P., primary, Salto-Tellez, Manuel, primary, James, Jacqueline A., primary, Hanna, Matthew G., primary, Melms, Johannes C., primary, Vallabhaneni, Sreeram, primary, Litchfield, Kevin, primary, Usaite, Ieva, primary, Biswas, Dhruva, primary, Bareja, Rohan, primary, Li, Hao Wei, primary, Martin, Maria Laura, primary, Dorsaint, Princesca, primary, Cavallo, Julie-Ann, primary, Li, Peng, primary, Pauli, Chantal, primary, Gottesdiener, Lee, primary, DiPardo, Benjamin J., primary, Hollmann, Travis J., primary, Merghoub, Taha, primary, Wen, Hannah Y., primary, Reis-Filho, Jorge S., primary, Riaz, Nadeem, primary, Su, Shin-San Michael, primary, Kalbasi, Anusha, primary, Vasan, Neil, primary, Powell, Simon N., primary, Wolchok, Jedd D., primary, Elemento, Olivier, primary, Swanton, Charles, primary, Shoushtari, Alexander N., primary, Parkes, Eileen E., primary, Izar, Benjamin, primary, and Bakhoum, Samuel F., primary

Published
2023
Full Text
View/download PDF

14. supplementary figures, from In-depth Clinical and Biological Exploration of DNA Damage Immune Response as a Biomarker for Oxaliplatin Use in Colorectal Cancer

Author

Malla, Sudhir B., primary, Fisher, David J., primary, Domingo, Enric, primary, Blake, Andrew, primary, Hassanieh, Sylvana, primary, Redmond, Keara L., primary, Richman, Susan D., primary, Youdell, Michael, primary, Walker, Steven M., primary, Logan, Gemma E., primary, Chatzipli, Aikaterina, primary, Amirkhah, Raheleh, primary, Humphries, Matthew P., primary, Craig, Stephanie G., primary, McDermott, Ultan, primary, Seymour, Matthew T., primary, Morton, Dion G., primary, Quirke, Philip, primary, West, Nicholas P., primary, Salto-Tellez, Manuel, primary, Kennedy, Richard D., primary, Johnston, Patrick G., primary, Tomlinson, Ian, primary, Koelzer, Viktor H., primary, Campo, Letitia, primary, Kaplan, Richard S., primary, Longley, Daniel B., primary, Lawler, Mark, primary, Maughan, Timothy S., primary, Brown, Louise C., primary, and Dunne, Philip D., primary

Published
2023
Full Text
View/download PDF

15. Supplementary Results from In-depth Clinical and Biological Exploration of DNA Damage Immune Response as a Biomarker for Oxaliplatin Use in Colorectal Cancer

Author

Malla, Sudhir B., primary, Fisher, David J., primary, Domingo, Enric, primary, Blake, Andrew, primary, Hassanieh, Sylvana, primary, Redmond, Keara L., primary, Richman, Susan D., primary, Youdell, Michael, primary, Walker, Steven M., primary, Logan, Gemma E., primary, Chatzipli, Aikaterina, primary, Amirkhah, Raheleh, primary, Humphries, Matthew P., primary, Craig, Stephanie G., primary, McDermott, Ultan, primary, Seymour, Matthew T., primary, Morton, Dion G., primary, Quirke, Philip, primary, West, Nicholas P., primary, Salto-Tellez, Manuel, primary, Kennedy, Richard D., primary, Johnston, Patrick G., primary, Tomlinson, Ian, primary, Koelzer, Viktor H., primary, Campo, Letitia, primary, Kaplan, Richard S., primary, Longley, Daniel B., primary, Lawler, Mark, primary, Maughan, Timothy S., primary, Brown, Louise C., primary, and Dunne, Philip D., primary

Published
2023
Full Text
View/download PDF

16. Experimental workflow from A Case-Matched Gender Comparison Transcriptomic Screen Identifies eIF4E and eIF5 as Potential Prognostic Markers in Male Breast Cancer

Author

Humphries, Matthew P., primary, Sundara Rajan, Sreekumar, primary, Droop, Alastair, primary, Suleman, Charlotte A.B., primary, Carbone, Carmine, primary, Nilsson, Cecilia, primary, Honarpisheh, Hedieh, primary, Cserni, Gabor, primary, Dent, Jo, primary, Fulford, Laura, primary, Jordan, Lee B., primary, Jones, J. Louise, primary, Kanthan, Rani, primary, Litwiniuk, Maria, primary, Di Benedetto, Anna, primary, Mottolese, Marcella, primary, Provenzano, Elena, primary, Shousha, Sami, primary, Stephens, Mark, primary, Walker, Rosemary A., primary, Kulka, Janina, primary, Ellis, Ian O., primary, Jeffery, Margaret, primary, Thygesen, Helene H., primary, Cappelletti, Vera, primary, Daidone, Maria G., primary, Hedenfalk, Ingrid A., primary, Fjällskog, Marie-Louise, primary, Melisi, Davide, primary, Stead, Lucy F., primary, Shaaban, Abeer M., primary, and Speirs, Valerie, primary

Published
2023
Full Text
View/download PDF

17. Cut-off determination and representative staining profiles for eIF proteins determined by immunohistochemistry from A Case-Matched Gender Comparison Transcriptomic Screen Identifies eIF4E and eIF5 as Potential Prognostic Markers in Male Breast Cancer

Author

Humphries, Matthew P., primary, Sundara Rajan, Sreekumar, primary, Droop, Alastair, primary, Suleman, Charlotte A.B., primary, Carbone, Carmine, primary, Nilsson, Cecilia, primary, Honarpisheh, Hedieh, primary, Cserni, Gabor, primary, Dent, Jo, primary, Fulford, Laura, primary, Jordan, Lee B., primary, Jones, J. Louise, primary, Kanthan, Rani, primary, Litwiniuk, Maria, primary, Di Benedetto, Anna, primary, Mottolese, Marcella, primary, Provenzano, Elena, primary, Shousha, Sami, primary, Stephens, Mark, primary, Walker, Rosemary A., primary, Kulka, Janina, primary, Ellis, Ian O., primary, Jeffery, Margaret, primary, Thygesen, Helene H., primary, Cappelletti, Vera, primary, Daidone, Maria G., primary, Hedenfalk, Ingrid A., primary, Fjällskog, Marie-Louise, primary, Melisi, Davide, primary, Stead, Lucy F., primary, Shaaban, Abeer M., primary, and Speirs, Valerie, primary

Published
2023
Full Text
View/download PDF

18. Interrogation of Oncomine{trade mark, serif} from A Case-Matched Gender Comparison Transcriptomic Screen Identifies eIF4E and eIF5 as Potential Prognostic Markers in Male Breast Cancer

Author

Humphries, Matthew P., primary, Sundara Rajan, Sreekumar, primary, Droop, Alastair, primary, Suleman, Charlotte A.B., primary, Carbone, Carmine, primary, Nilsson, Cecilia, primary, Honarpisheh, Hedieh, primary, Cserni, Gabor, primary, Dent, Jo, primary, Fulford, Laura, primary, Jordan, Lee B., primary, Jones, J. Louise, primary, Kanthan, Rani, primary, Litwiniuk, Maria, primary, Di Benedetto, Anna, primary, Mottolese, Marcella, primary, Provenzano, Elena, primary, Shousha, Sami, primary, Stephens, Mark, primary, Walker, Rosemary A., primary, Kulka, Janina, primary, Ellis, Ian O., primary, Jeffery, Margaret, primary, Thygesen, Helene H., primary, Cappelletti, Vera, primary, Daidone, Maria G., primary, Hedenfalk, Ingrid A., primary, Fjällskog, Marie-Louise, primary, Melisi, Davide, primary, Stead, Lucy F., primary, Shaaban, Abeer M., primary, and Speirs, Valerie, primary

Published
2023
Full Text
View/download PDF

19. Supplementary Data from In-depth Clinical and Biological Exploration of DNA Damage Immune Response as a Biomarker for Oxaliplatin Use in Colorectal Cancer

Author

Malla, Sudhir B., primary, Fisher, David J., primary, Domingo, Enric, primary, Blake, Andrew, primary, Hassanieh, Sylvana, primary, Redmond, Keara L., primary, Richman, Susan D., primary, Youdell, Michael, primary, Walker, Steven M., primary, Logan, Gemma E., primary, Chatzipli, Aikaterina, primary, Amirkhah, Raheleh, primary, Humphries, Matthew P., primary, Craig, Stephanie G., primary, McDermott, Ultan, primary, Seymour, Matthew T., primary, Morton, Dion G., primary, Quirke, Philip, primary, West, Nicholas P., primary, Salto-Tellez, Manuel, primary, Kennedy, Richard D., primary, Johnston, Patrick G., primary, Tomlinson, Ian, primary, Koelzer, Viktor H., primary, Campo, Letitia, primary, Kaplan, Richard S., primary, Longley, Daniel B., primary, Lawler, Mark, primary, Maughan, Timothy S., primary, Brown, Louise C., primary, and Dunne, Philip D., primary

Published
2023
Full Text
View/download PDF

20. Subcellular Epithelial HMGB1 Expression Is Associated with Colorectal Neoplastic Progression, Male Sex, Mismatch Repair Protein Expression, Lymph Node Positivity, and an ‘Immune Cold’ Phenotype Associated with Poor Survival

Author

Porter, Ross J., primary, Murray, Graeme I., additional, Hapca, Sandra, additional, Hay, Andrew, additional, Craig, Stephanie G., additional, Humphries, Matthew P., additional, James, Jacqueline A., additional, Salto-Tellez, Manuel, additional, Brice, Daniel P., additional, Berry, Susan H., additional, and McLean, Mairi H., additional

Published
2023
Full Text
View/download PDF

23. Technical note on the exploration of COVID-19 in autopsy material

Author

Humphries, Matthew Phillip, primary, Bingham, Victoria, additional, Abdullah Sidi, Fatima, additional, Craig, Stephanie, additional, Lara, Beatrize, additional, El-daly, Hesham, additional, O'Doherty, Nicole, additional, Maxwell, Perry, additional, Lewis, Claire, additional, McQuaid, Stephen, additional, Lyness, James, additional, James, Jacqueline, additional, Snead, David R J, additional, and Salto-Tellez, Manuel, additional

Published
2023
Full Text
View/download PDF

25. ICOSeg: Real-Time ICOS Protein Expression Segmentation from Immunohistochemistry Slides Using a Lightweight Conv-Transformer Network

Author

Singh, Vivek Kumar, primary, Sarker, Md. Mostafa Kamal, additional, Makhlouf, Yasmine, additional, Craig, Stephanie G., additional, Humphries, Matthew P., additional, Loughrey, Maurice B., additional, James, Jacqueline A., additional, Salto-Tellez, Manuel, additional, O’Reilly, Paul, additional, and Maxwell, Perry, additional

Published
2022
Full Text
View/download PDF

27. Activation of a cGAS-STING-mediated immune response predicts response to neoadjuvant chemotherapy in early breast cancer

Author

Parkes, Eileen E, Savage, Kienan I, Lioe, Tong, Boyd, Clinton, Halliday, Sophia, Walker, Steven M, Lowry, Keith, Knight, Laura, Buckley, Niamh E, Grogan, Andrena, Logan, Gemma E, Clayton, Alison, Hurwitz, Jane, Kirk, Stephen J, Xu, Jiamei, Sidi, Fatima Abdullahi, Humphries, Matthew P, Bingham, Victoria, Neo-DDIR Investigators, James, Jaqueline A, James, Colin R, Paul Harkin, D, Kennedy, Richard D, and McIntosh, Stuart A

Abstract

BACKGROUND: The DNA-damage immune-response (DDIR) signature is an immune-driven gene expression signature retrospectively validated as predicting response to anthracycline-based therapy. This feasibility study prospectively evaluates the use of this assay to predict neoadjuvant chemotherapy response in early breast cancer. METHODS: This feasibility study assessed the integration of a novel biomarker into clinical workflows. Tumour samples were collected from patients receiving standard of care neoadjuvant chemotherapy (FEC + /-taxane and anti-HER2 therapy as appropriate) at baseline, mid- and post-chemotherapy. Baseline DDIR signature scores were correlated with pathological treatment response. RNA sequencing was used to assess chemotherapy/response-related changes in biologically linked gene signatures. RESULTS: DDIR signature reports were available within 14 days for 97.8% of 46 patients (13 TNBC, 16 HER2 + ve, 27 ER + HER2-ve). Positive scores predicted response to treatment (odds ratio 4.67 for RCB 0-1 disease (95% CI 1.13-15.09, P = 0.032)). DDIR positivity correlated with immune infiltration and upregulated immune-checkpoint gene expression. CONCLUSIONS: This study validates the DDIR signature as predictive of response to neoadjuvant chemotherapy which can be integrated into clinical workflows, potentially identifying a subgroup with high sensitivity to anthracycline chemotherapy. Transcriptomic data suggest induction with anthracycline-containing regimens in immune restricted, "cold" tumours may be effective for immune priming. TRIAL REGISTRATION: Not applicable (non-interventional study). CRUK Internal Database Number 14232.

Published
2021

28. Orthogonal MET analysis in a population‐representative stage II–III colon cancer cohort: prognostic and potential therapeutic implications

Author

Craig, Stephanie G., primary, Mende, Svenja, additional, Humphries, Matthew P., additional, Bingham, Victoria, additional, Viratham Pulsawatdi, Amélie, additional, Loughrey, Maurice B., additional, Coleman, Helen G., additional, McQuaid, Stephen, additional, Wilson, Richard H., additional, Van Schaeybroeck, Sandra, additional, James, Jacqueline A., additional, and Salto‐Tellez, Manuel, additional

Published
2021
Full Text
View/download PDF

29. The Potential of Digital Image Analysis to Determine Tumor Cell Content in Biobanked Formalin-Fixed, Paraffin-Embedded Tissue Samples

Author

Greene, Christine, primary, O'Doherty, Edwina, additional, Abdullahi Sidi, Fatima, additional, Bingham, Victoria, additional, Fisher, Natalie C., additional, Humphries, Matthew P., additional, Craig, Stephanie G., additional, Harewood, Louise, additional, McQuaid, Stephen, additional, Lewis, Claire, additional, and James, Jacqueline, additional

Published
2021
Full Text
View/download PDF

31. HistoClean: Open-source Software for Histological Image Pre-processing and Augmentation to Improve Development of Robust Convolutional Neural Networks

Author

McCombe, Kris D., primary, Craig, Stephanie G., additional, Pulsawatdi, Amélie Viratham, additional, Quezada-Marín, Javier I., additional, Hagan, Matthew, additional, Rajendran, Simon, additional, Humphries, Matthew P., additional, Bingham, Victoria, additional, Salto-Tellez, Manuel, additional, Gault, Richard, additional, and James, Jacqueline A., additional

Published
2021
Full Text
View/download PDF

32. Colonic epithelial cathelicidin (LL‐37) expression intensity is associated with progression of colorectal cancer and presence of CD8+ T cell infiltrate

Author

Porter, Ross J, primary, Murray, Graeme I, additional, Alnabulsi, Abdo, additional, Humphries, Matthew P, additional, James, Jacqueline A, additional, Salto‐Tellez, Manuel, additional, Craig, Stephanie G, additional, Wang, Ji M, additional, Yoshimura, Teizo, additional, and McLean, Mairi H, additional

Published
2021
Full Text
View/download PDF

33. Evolutionary genetic algorithm identifies IL2RB as a potential predictive biomarker for immune-checkpoint therapy in colorectal cancer

Author

Alderdice, Matthew, primary, Craig, Stephanie G, additional, Humphries, Matthew P, additional, Gilmore, Alan, additional, Johnston, Nicole, additional, Bingham, Victoria, additional, Coyle, Vicky, additional, Senevirathne, Seedevi, additional, Longley, Daniel B, additional, Loughrey, Maurice B, additional, McQuaid, Stephen, additional, James, Jacqueline A, additional, Salto-Tellez, Manuel, additional, Lawler, Mark, additional, and McArt, Darragh G, additional

Published
2021
Full Text
View/download PDF

34. In-depth Clinical and Biological Exploration of DNA Damage Immune Response as a Biomarker for Oxaliplatin Use in Colorectal Cancer

Author

Malla, Sudhir B., primary, Fisher, David J., additional, Domingo, Enric, additional, Blake, Andrew, additional, Hassanieh, Sylvana, additional, Redmond, Keara L., additional, Richman, Susan D., additional, Youdell, Michael, additional, Walker, Steven M., additional, Logan, Gemma E., additional, Chatzipli, Aikaterina, additional, Amirkhah, Raheleh, additional, Humphries, Matthew P., additional, Craig, Stephanie G., additional, McDermott, Ultan, additional, Seymour, Matthew T., additional, Morton, Dion G., additional, Quirke, Philip, additional, West, Nicholas P., additional, Salto-Tellez, Manuel, additional, Kennedy, Richard D., additional, Johnston, Patrick G., additional, Tomlinson, Ian, additional, Koelzer, Viktor H., additional, Campo, Letitia, additional, Kaplan, Richard S., additional, Longley, Daniel B., additional, Lawler, Mark, additional, Maughan, Timothy S., additional, Brown, Louise C., additional, and Dunne, Philip D., additional

Published
2021
Full Text
View/download PDF

35. Metastasis and Immune Evasion from Extracellular cGAMP Hydrolysis

Author

Li, Jun, primary, Duran, Mercedes A., additional, Dhanota, Ninjit, additional, Chatila, Walid K., additional, Bettigole, Sarah E., additional, Kwon, John, additional, Sriram, Roshan K., additional, Humphries, Matthew P., additional, Salto-Tellez, Manuel, additional, James, Jacqueline A., additional, Hanna, Matthew G., additional, Melms, Johannes C., additional, Vallabhaneni, Sreeram, additional, Litchfield, Kevin, additional, Usaite, Ieva, additional, Biswas, Dhruva, additional, Bareja, Rohan, additional, Li, Hao Wei, additional, Martin, Maria Laura, additional, Dorsaint, Princesca, additional, Cavallo, Julie-Ann, additional, Li, Peng, additional, Pauli, Chantal, additional, Gottesdiener, Lee, additional, DiPardo, Benjamin J., additional, Hollmann, Travis J., additional, Merghoub, Taha, additional, Wen, Hannah Y., additional, Reis-Filho, Jorge S., additional, Riaz, Nadeem, additional, Su, Shin-San Michael, additional, Kalbasi, Anusha, additional, Vasan, Neil, additional, Powell, Simon N., additional, Wolchok, Jedd D., additional, Elemento, Olivier, additional, Swanton, Charles, additional, Shoushtari, Alexander N., additional, Parkes, Eileen E., additional, Izar, Benjamin, additional, and Bakhoum, Samuel F., additional

Published
2020
Full Text
View/download PDF

37. Automated tumour recognition and digital pathology scoring unravels new role for PD-L1 in predicting good outcome in ER-/HER2+ breast cancer

Author

Humphries, Matthew P., Hynes, Sean, Bingham, Victoria, Cougot, Delphine, James, Jacqueline, Patel-Socha, Farah, Parkes, Eileen E., Blayney, Jaine K., O'Rorke, Michael A., Irwin, Gareth W., McArt, Darragh G., Kennedy, Richard D., Mullan, Paul B., McQuaid, Stephen, Salto-Tellez, Manuel, and Buckley, Niamh E.

Subjects
SDG 3 - Good Health and Well-being, Article Subject, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, lcsh:RC254-282, Research Article
Abstract

The role of PD-L1 as a prognostic and predictive biomarker is an area of great interest. However, there is a lack of consensus on how to deliver PD-L1 as a clinical biomarker. At the heart of this conundrum is the subjective scoring of PD-L1 IHC in most studies to date. Current standard scoring systems involve separation of epithelial and inflammatory cells and find clinical significance in different percentages of expression, e.g., above or below 1%. Clearly, an objective, reproducible and accurate approach to PD-L1 scoring would bring a degree of necessary consistency to this landscape. Using a systematic comparison of technologies and the application of QuPath, a digital pathology platform, we show that high PD-L1 expression is associated with improved clinical outcome in Triple Negative breast cancer in the context of standard of care (SoC) chemotherapy, consistent with previous findings. In addition, we demonstrate for the first time that high PD-L1 expression is also associated with better outcome in ER- disease as a whole including HER2+ breast cancer. We demonstrate the influence of antibody choice on quantification and clinical impact with the Ventana antibody (SP142) providing the most robust assay in our hands. Through sampling different regions of the tumour, we show that tumour rich regions display the greatest range of PD-L1 expression and this has the most clinical significance compared to stroma and lymphoid rich areas. Furthermore, we observe that both inflammatory and epithelial PD-L1 expression are associated with improved survival in the context of chemotherapy. Moreover, as seen with PD-L1 inhibitor studies, a low threshold of PD-L1 expression stratifies patient outcome. This emphasises the importance of using digital pathology and precise biomarker quantitation to achieve accurate and reproducible scores that can discriminate low PD-L1 expression.

Published
2020

38. Additional file 2 of The adaptive immune and immune checkpoint landscape of neoadjuvant treated esophageal adenocarcinoma using digital pathology quantitation

Author

Humphries, Matthew P., Craig, Stephanie G., Kacprzyk, Rafal, Fisher, Natalie C., Bingham, Victoria, McQuaid, Stephen, Murray, Graeme I., McManus, Damian, Turkington, Richard C., James, Jacqueline, and Salto-Tellez, Manuel

Subjects
Data_FILES
Abstract

Additional file 2: Table S2. R.O.C Cut Offs.

Published
2020
Full Text
View/download PDF

39. Additional file 4 of The adaptive immune and immune checkpoint landscape of neoadjuvant treated esophageal adenocarcinoma using digital pathology quantitation

Author

Humphries, Matthew P., Craig, Stephanie G., Kacprzyk, Rafal, Fisher, Natalie C., Bingham, Victoria, McQuaid, Stephen, Murray, Graeme I., McManus, Damian, Turkington, Richard C., James, Jacqueline, and Salto-Tellez, Manuel

Subjects
ComputingMethodologies_PATTERNRECOGNITION
Abstract

Additional file 4: Figure S1. Robust digital pathology workflow. Flow diagram demonstrates conceptually the process of biomarker quantification, strict quality control and data validation steps.

Published
2020
Full Text
View/download PDF

40. Additional file 3 of The adaptive immune and immune checkpoint landscape of neoadjuvant treated esophageal adenocarcinoma using digital pathology quantitation

Author

Humphries, Matthew P., Craig, Stephanie G., Kacprzyk, Rafal, Fisher, Natalie C., Bingham, Victoria, McQuaid, Stephen, Murray, Graeme I., McManus, Damian, Turkington, Richard C., James, Jacqueline, and Salto-Tellez, Manuel

Abstract

Additional file 3: Table S3. Discovery Cohort Multivariate Analysis Excluding TRG 1 and 2 cases.

Published
2020
Full Text
View/download PDF

42. Identifying mismatch repair‐deficient colon cancer: near‐perfect concordance between immunohistochemistry and microsatellite instability testing in a large, population‐based series

Author

Loughrey, Maurice B, primary, McGrath, Jason, additional, Coleman, Helen G, additional, Bankhead, Peter, additional, Maxwell, Perry, additional, McGready, Claire, additional, Bingham, Victoria, additional, Humphries, Matthew P, additional, Craig, Stephanie G, additional, McQuaid, Stephen, additional, Salto‐Tellez, Manuel, additional, and James, Jacqueline A, additional

Published
2020
Full Text
View/download PDF

44. A robust multiplex immunofluorescence and digital pathology workflow for the characterisation of the tumour immune microenvironment

Author

Viratham Pulsawatdi, Amélie, primary, Craig, Stephanie G., additional, Bingham, Victoria, additional, McCombe, Kris, additional, Humphries, Matthew P., additional, Senevirathne, Seedevi, additional, Richman, Susan D., additional, Quirke, Phil, additional, Campo, Leticia, additional, Domingo, Enric, additional, Maughan, Timothy S., additional, James, Jacqueline A., additional, and Salto‐Tellez, Manuel, additional

Published
2020
Full Text
View/download PDF

48. Colonic epithelial cathelicidin (LL‐37) expression intensity is associated with progression of colorectal cancer and presence of CD8+ T cell infiltrate.

Author

Porter, Ross J, Murray, Graeme I, Alnabulsi, Abdo, Humphries, Matthew P, James, Jacqueline A, Salto‐Tellez, Manuel, Craig, Stephanie G, Wang, Ji M, Yoshimura, Teizo, and McLean, Mairi H

Subjects
COLORECTAL cancer, T cells, CANCER invasiveness, SKIN permeability, GENDER, CANCER-related mortality
Abstract

Colorectal cancer (CRC) remains a leading cause of cancer mortality. Here, we define the colonic epithelial expression of cathelicidin (LL‐37) in CRC. Cathelicidin exerts pleotropic effects including anti‐microbial and immunoregulatory functions. Genetic knockout of cathelicidin led to increased size and number of colorectal tumours in the azoxymethane‐induced murine model of CRC. We aimed to translate this to human disease. The expression of LL‐37 in a large (n = 650) fully characterised cohort of treatment‐naïve primary human colorectal tumours and 50 matched normal mucosa samples with associated clinical and pathological data (patient age, gender, tumour site, tumour stage [UICC], presence or absence of extra‐mural vascular invasion, tumour differentiation, mismatch repair protein status, and survival to 18 years) was assessed by immunohistochemistry. The biological consequences of LL‐37 expression on the epithelial barrier and immune cell phenotype were assessed using targeted quantitative PCR gene expression of epithelial permeability (CLDN2, CLDN4, OCLN, CDH1, and TJP1) and cytokine (IL‐1β, IL‐18, IL‐33, IL‐10, IL‐22, and IL‐27) genes in a human colon organoid model, and CD3+, CD4+, and CD8+ lymphocyte phenotyping by immunohistochemistry, respectively. Our data reveal that loss of cathelicidin is associated with human CRC progression, with a switch in expression intensity an early feature of CRC. LL‐37 expression intensity is associated with CD8+ T cell infiltrate, influenced by tumour characteristics including mismatch repair protein status. There was no effect on epithelial barrier gene expression. These data offer novel insights into the contribution of LL‐37 to the pathogenesis of CRC and as a therapeutic molecule. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

49. Critical Appraisal of Programmed Death Ligand 1 Reflex Diagnostic Testing: Current Standards and Future Opportunities

Author

Humphries, Matthew P, McQuaid, Stephen, Craig, Stephanie G, Bingham, Victoria, Maxwell, Perry, Maurya, Manisha, McLean, Fiona, Sampson, James, Higgins, Patricia, Greene, Christine, James, Jacqueline, and Salto-Tellez, Manuel

Abstract

INTRODUCTION: Patient suitability to anti-programmed death ligand 1 (PD-L1) immune checkpoint inhibition is key to the treatment of NSCLC. We present, applied to PD-L1 testing: a comprehensive cross-validation of two immunohistochemistry (IHC) clones; our descriptive experience in diagnostic reflex testing; the concordance of IHC to in situ RNA (RNA-ISH); and application of digital pathology.METHODS: Eight hundred thirteen NSCLC tumor samples collected from 564 diagnostic samples were analyzed prospectively, and 249 diagnostic samples analyzed retrospectively in tissue microarray format. Validated methods for IHC and RNA-ISH were tested in tissue microarrays and full sections and the QuPath system were used for digital pathology analysis.RESULTS: Antibody concordance of clones SP263 and 22C3 validation was 97% to 98% in squamous cell carcinoma and adenocarcinomas, respectively. Clinical NSCLC cases were reported as PD-L1-negative (48%), 1% to 49% (23%), and more than 50% (29%), with differences associated to tissue-type and EGFR status. Comparison of IHC and RNA-ISH was highly concordant in both subgroups. Comparison of digital assessment versus manual assessment was highly concordant. Discrepancies were mostly around the 1% clinical threshold. Challenging IHC interpretation included 1) calculating the total tumor cell denominator and the nature of PD-L1 expressing cell aggregates in cytology samples; 2) peritumoral expression of positive immune cells; 3) calculation of positive tumor percentages around clinical thresholds; and 4) relevance of the 100 malignant cell rule.CONCLUSIONS: Sample type and EGFR status dictate differences in the expected percentage of PD-L1 expression. Analysis of PD-L1 is challenging, and interpretative guidelines are discussed. PD-L1 evaluations by RNA-ISH and digital pathology appear reliable, particularly in adenocarcinomas.

Published
2019

50. ESARDA Bulletin n.58

Author

KRIEGER THOMAS, AYMANNS KATHARINA, REZNICZEK ARNOLD, NIEMEYER IRMGARD, CALDEIRA BALKESTAHL LI, ELTER ZS., GRAPE SOPHIE, ROSSA RICCARDO, BORELLA A., BRANGER ERIK, JANSSON PETER, ZAIOUN HUGO, SMARTT HEIDI A., BENIN ANNABELLE I., CORBIN CODY, CUSTER JOYCE, FENG PATRICK L., HUMPHRIES MATTHEW, JONES AMANDA, MYLLENBECK NICHOLAS R., CLEMENTI CHIARA, CAPINERI LORENZO, LITTMANN FRANCOIS, BENZ JACOB, ALLEN KEIR, AF EKENSTAM G., HUTSVEIT STYRKAAR, STRINGA ELENA, and DE LUCA ANDREA

Abstract

ESARDA is an association initially formed to advance and harmonize research and development for nuclear safeguards whose scope has in recent year expanded as the number and type of its working groups’ activities below indicates. Esarda is currently composed of about 30 laboratories, private and governmental institutions worldwide. Within Esarda (http://esarda.jrc.ec.europa.eu/), a number working groups have been over the years established and active namely: Techniques and Standards for Destructive Analysis, Techniques and Standards for Non-Destructive Analysis, Containment and Surveillance, Novel Approaches / Novel Technologies, Implementation of Safeguards, Verification Technologies and Methodologies, Training and Knowledge Management, Editorial Committee. ESARDA publishes a Bulletin containing peer reviewed scientific related to nuclear Safeguards, verification and non-proliferation. This publication appears generally twice a year. In addition, thematic special issues are published as proposed by the ESARDA community. The Bulletin Editorial Board is composed of about 10 experts in the various technical and scientific fields related to safeguards. They are all actively engaged in safeguards R&D or in safeguards implementation and other fields. The Editorial Board decides the contents of the Bulletin, selects the papers to be published and reviews them before publication. All ESARDA editorial activities are carried out at JRC in Ispra. Scientific papers submitted for publication are reviewed by independent authors and by members of the Editorial Committee. The Bulletin is currently submitted to Scopus for evaluation in view of citation. ESARDA Bulletin is published jointly by ESARDA and the Joint Research Centre of the European Commission and distributed free of charge to over 1000 registered members, libraries and institutions worldwide., JRC.G.II.7-Nuclear security

Published
2019

Catalog

Books, media, physical & digital resources
See catalog results